MUFG Securities EMEA plc Has $1.34 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Key Points

• MUFG Securities EMEA plc decreased its holdings in Sarepta Therapeutics by 73.4% during the first quarter, selling 58,001 shares, and now owns 20,999 shares valued at approximately $1.34 million.
• Analysts have mixed sentiments about Sarepta Therapeutics, with Wells Fargo lifting its target price to $50.00 and giving an "overweight" rating, while Evercore ISI downgraded it from "outperform" to "inline" with a $50.00 target.
• In its recent earnings report, Sarepta Therapeutics posted an earnings per share (EPS) of $2.02, exceeding expectations and showing a 68.4% increase in revenue year-over-year.

MUFG Securities EMEA plc cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 73.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 20,999 shares of the biotechnology company's stock after selling 58,001 shares during the period. MUFG Securities EMEA plc's holdings in Sarepta Therapeutics were worth $1,340,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SRPT. Capital International Investors lifted its position in Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Sarepta Therapeutics by 438.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after purchasing an additional 580,123 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after purchasing an additional 285,100 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $30,398,000. Finally, Summit Partners Public Asset Management LLC raised its position in shares of Sarepta Therapeutics by 174.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 379,150 shares of the biotechnology company's stock valued at $46,101,000 after purchasing an additional 241,032 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of recent analyst reports. Robert W. Baird upped their target price on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Leerink Partnrs lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Wolfe Research started coverage on Sarepta Therapeutics in a report on Tuesday, June 17th. They issued a "peer perform" rating for the company. Finally, Oppenheimer upgraded Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $30.00 to $37.00 in a report on Tuesday, July 29th. Five equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $44.17.

Sarepta Therapeutics Stock Up 1.5%

Shares of SRPT traded up $0.27 during midday trading on Friday, reaching $18.23. 10,382,506 shares of the stock were exchanged, compared to its average volume of 23,065,296. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $144.22. The firm has a 50 day simple moving average of $21.73 and a 200-day simple moving average of $56.48. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -20.95 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. The firm's revenue for the quarter was up 68.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.07 EPS. Research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.